110 filings
Page 5 of 6
8-K
9qh8syxavfb c1fyae
10 Aug 16
Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial
12:00am
8-K
8e5feq0
5 Aug 16
Entry into a Material Definitive Agreement
12:00am
8-K
lp9z pisutlfg
3 Aug 16
Inotek Pharmaceuticals Announces Proposed Public Offering of $50
12:00am
8-K
mute678x2gwk ub60a
1 Aug 16
Results of Operations and Financial Condition
12:00am
8-K
8ljzft8v5izs1
22 Jul 16
Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent
12:00am
8-K
w55hap4kuljzaq8r
14 Jul 16
Other Events
12:00am
8-K
5e8bts
27 Jun 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
nqtiw4
11 May 16
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
12:00am
8-K
71ae5 wt9e9qit26sz
4 Apr 16
Inotek Pharmaceuticals Announces Changes to Board of Directors
12:00am
8-K
gyfpnx0vub qhtld2thf
25 Mar 16
Other Events
12:00am
8-K
k40ml24k6hs1w2f389
23 Mar 16
Inotek Pharmaceuticals Corporation Reports Fiscal Year 2015 Financial Results and Operational Highlights
12:00am
8-K
087kgf8v
11 Mar 16
Inotek Pharmaceuticals Strengthens Patent Estate for Lead Product CandidateTrabodenoson
12:00am
8-K
ogge7ofgylf9615d x84
26 Feb 16
Entry into a Material Definitive Agreement
12:00am
8-K
jl1 wipc4e4
12 Jan 16
Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors
12:00am
8-K
ji1baj
12 Nov 15
Inotek Pharmaceuticals Corporation Reports Third Quarter 2015
12:00am
8-K/A
mtbg9bossp8p7w num
23 Oct 15
Departure of Directors or Certain Officers
12:00am
8-K
q5fdw
16 Oct 15
Inotek Pharmaceuticals Initiates Dosing of MATRx-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma
12:00am
8-K
wy0uwzo
13 Oct 15
Inotek Pharmaceuticals Appoints Gary M. Phillips, MD, MBA, to Board of Directors
12:00am
8-K
mlm 7g9tn66
18 Aug 15
Inotek Pharmaceuticals Corporation Announces Closing of $79.2 Million
12:00am
8-K
epo9hm435qu626vv
17 Aug 15
Inotek Pharmaceuticals Corporation Announces Pricing of $68.9 Million Public Offering
12:00am